Generation Bio to Present at William Blair Biotech Focus Conference
Generation Bio, a leader in genetic medicines, announced that CEO Geoff McDonough will present at the William Blair Biotech Focus Conference on July 15, 2021, at 9:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Generation Bio, a leader in genetic medicines, announced that CEO Geoff McDonough will present at the William Blair Biotech Focus Conference on July 15, 2021, at 9:00 a.m. ET. The event will feature a live webcast available on their investor website, with a replay accessible for 30 days. Generation Bio focuses on developing non-viral gene therapies aimed at providing durable treatments for various diseases. Their innovative platform utilizes closed-ended DNA and a specialized delivery system to target specific tissues for effective therapy.
Details
News Market Reaction – GBIO
The recorded move for GBIO in the trading session of this news was +1.40%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff McDonough, M.D., president and chief executive officer, will present at the William Blair Biotech Focus Conference 2021 on Thursday, July 15, at 9:00 a.m. ET.
A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event.
About Generation Bio
Generation Bio is an innovative genetic medicines company focused on creating a new class of non-viral gene therapy to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral platform incorporates a proprietary, high-capacity DNA construct called closed-ended DNA, or ceDNA; a cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The platform is designed to enable multi-year durability from a single dose of ceDNA and to allow titration and redosing if needed. The ctLNP is designed to deliver large genetic payloads, including multiple genes, to specific tissues to address a wide range of indications. The company’s efficient, scalable manufacturing process supports Generation Bio’s mission to extend the reach of gene therapy to more people, living with more diseases, in more places around the world.
For more information, please visit www.generationbio.com.
Contact:
Investors
Maren Killackey
Generation Bio
mkillackey@generationbio.com
541-646-2420
Media
Alicia Webb
Generation Bio
awebb@generationbio.com
847-254-4275
Stephanie Simon
Ten Bridge Communications
stephanie@tenbridgecommunications.com
617-581-9333
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.